What is compounded semaglutide?
Semaglutide is the active ingredient in Novo Nordisk's brand-name products Ozempic (FDA-approved 2017 for type 2 diabetes), Wegovy (FDA-approved 2021 for chronic weight management; 2024 indication added for cardiovascular risk reduction), and Rybelsus (oral semaglutide for type 2 diabetes, 2019). It is a GLP-1 receptor agonist with the largest single-molecule clinical evidence base in the class, including the STEP trial series for weight management and the SELECT trial for cardiovascular outcomes.
Compounded semaglutide is an injectable preparation containing the same active pharmaceutical ingredient, prepared by a licensed compounding pharmacy operating under section 503A (traditional patient-specific compounding) or 503B (outsourcing facility) of the Federal Food, Drug, and Cosmetic Act. Compounded semaglutide is not FDA-approved — FDA approves drug products from drug companies, not compounded preparations. FDA regulates the compounding pharmacy industry.
Is compounded semaglutide legal?
The legal status of compounded semaglutide depends on FDA drug shortage status and on state pharmacy law.
Shortage rule
Under section 503A of the FD&C Act, a traditional compounding pharmacy cannot compound a drug that is "essentially a copy" of a commercially available FDA-approved drug, except in narrow circumstances. One major exception applies during an FDA-declared drug shortage.
Semaglutide was on the FDA Drug Shortage list during peak demand in 2022-2024, enabling compounded semaglutide to be widely available through 503B outsourcing facilities and 503A pharmacies. As of 2026, semaglutide's shortage status has fluctuated; in periods where the FDA has declared the shortage resolved, the broad compounding exception for "essentially a copy" preparations does not apply. Compounded semaglutide is then permitted only when there is a specific clinical need for the individual patient that the commercial product cannot meet — for example, a dose strength not commercially available, an excipient allergy, or another documented clinical reason.
State variation
State boards of pharmacy can add restrictions independent of FDA shortage status. Some states have moved to limit compounded GLP-1 medications regardless of federal availability. Telehealth platforms operate within state-by-state rules; this is one reason a service may be available in some states and not others.
FDA warnings
FDA has issued multiple consumer alerts about unsafe compounded semaglutide products, including products sold from unlicensed sources, products containing the salt form (semaglutide sodium) rather than the base form used in approved products, and products with no documented testing for sterility or potency. The salt forms have not been studied for safety or efficacy in this context.
Is compounded semaglutide an option for you?
A licensed clinician can assess whether compounded semaglutide is clinically appropriate and legally available in your state.
See If You Qualify →Sponsored link. We earn a commission when you sign up. Medical eligibility determined by licensed providers. Disclosure
Compounded semaglutide vs Ozempic and Wegovy
| Factor | Compounded semaglutide | Ozempic / Wegovy (brand-name) |
|---|---|---|
| Active ingredient | Semaglutide (same as brand-name when properly prepared) | Semaglutide |
| Manufacturer | Licensed 503A or 503B compounding pharmacy | Novo Nordisk |
| FDA approval | Not FDA-approved as a drug product | FDA-approved: Ozempic 2017, Wegovy 2021 |
| Typical cost | $150-$400/month via telehealth | Ozempic ~$1,000/month; Wegovy ~$1,350/month |
| Dose flexibility | Custom doses possible when clinically justified | Fixed strengths |
| Quality controls | USP <797> sterile compounding; varies by pharmacy | GMP manufacturing; FDA-regulated |
| Insurance | Generally self-pay | Sometimes covered (T2D commonly; weight management variably) |
Compounded semaglutide cost
Typical pricing for compounded semaglutide through telehealth runs $150-$400 per month, depending on:
- Dose. Higher doses cost more.
- Provider model. Some platforms bundle clinician visits and medication; others charge separately.
- Pharmacy. Pharmacy cost structures vary.
- Subscription length. Quarterly subscriptions typically have lower per-month pricing.
Compounded semaglutide is generally not covered by health insurance because it is not an FDA-approved drug product. Self-pay is the rule.
How to evaluate a compounding pharmacy
Pharmacy quality matters more for compounded medications than for brand-name products. Look for:
- Licensure. Active state board of pharmacy license; for 503B, FDA registration.
- USP <797> compliance. The standard for sterile compounding; reputable pharmacies maintain certification.
- Third-party testing. Independent verification of potency (does it contain the labeled amount?), sterility (no bacterial or fungal contamination?), and absence of impurities. Reputable pharmacies provide certificates of analysis on request.
- API sourcing. Semaglutide active pharmaceutical ingredient should come from FDA-registered facilities. Be wary of pharmacies that cannot or will not document API origin.
- Cold-chain shipping. Semaglutide requires refrigeration; check that shipments use insulated packaging with temperature monitoring.
- 503A vs 503B. 503B outsourcing facilities have FDA oversight and additional GMP-like requirements; 503A pharmacies serve patient-specific prescriptions.
If a telehealth service is unwilling to identify the pharmacy that will fill your prescription, that is a meaningful information gap. A reputable platform is transparent about its pharmacy partners.
Is compounded semaglutide safe?
The active ingredient in properly compounded semaglutide is the same as in Ozempic and Wegovy. The pharmacologic side effect profile (GI side effects, pancreatitis warning, gallbladder disease, kidney injury, thyroid C-cell boxed warning) is therefore the same. Safety differences between compounded and brand-name semaglutide are about manufacturing quality, sterility, dosing accuracy, and ingredient identity — not about the drug itself.
FDA warnings about unsafe compounded products have included reports of:
- Sterility failures (contamination).
- Potency variations (more or less semaglutide than labeled).
- Use of semaglutide salt forms not studied for safety.
- Mislabeling or adulteration.
These risks are minimized by working with telehealth platforms that partner with reputable, USP <797>-compliant compounding pharmacies that perform third-party testing.
Side effects of compounded semaglutide
Compounded semaglutide carries the same expected side effect profile as brand-name semaglutide:
- Common: nausea, vomiting, diarrhea, constipation, abdominal pain. Most common during dose escalation.
- Uncommon but serious: acute pancreatitis, gallbladder disease, kidney injury, severe gastroparesis, hypoglycemia (especially with insulin or sulfonylureas).
- Boxed warning: thyroid C-cell tumors based on rodent data — contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN-2.
- Recent signals: non-arteritic anterior ischemic optic neuropathy (NAION) reports under FDA review; causation not established.
See our complete GLP-1 side effects guide.
How to get compounded semaglutide through telehealth
- Online medical history. Detailed intake covering weight history, medical conditions, medications, allergies, contraindications.
- Video evaluation with a licensed clinician. A physician, nurse practitioner, or physician assistant licensed in your state reviews your history, asks follow-up questions, and determines whether semaglutide is appropriate — and whether a compounded version meets the current legal criteria.
- Optional labs. Some clinicians require baseline HbA1c, lipid panel, and metabolic panel.
- Prescription and dispensing. If approved, prescription is sent to a partnered compounding pharmacy that prepares your specific preparation and ships it to you with appropriate temperature control.
- Follow-up. Most programs include scheduled check-ins or as-needed access to manage titration and side effects.
Bottom line
Compounded semaglutide can be a reasonable option for some patients — particularly when brand-name Ozempic or Wegovy is unaffordable, when the clinician determines that a compounded preparation is legally permitted and clinically appropriate, and when the compounding pharmacy meets quality standards. It is not appropriate when brand-name access is comparable, when the compounded product appears to be a direct copy with no clinical rationale, or when the pharmacy cannot document API origin and testing.
The legal landscape changes with FDA shortage declarations and state regulations. Working with a licensed clinician through a transparent telehealth platform is the safest way to navigate that landscape.
See if compounded semaglutide is right for you
A licensed clinician via telehealth can review your eligibility and explain the legal and clinical options for your situation.
Check Your Eligibility →Sponsored link. We earn a commission when you sign up. Medical eligibility determined by licensed providers. Disclosure